Autism spectrum disorders (ASD) are a collection of neurobehavioral and neurological dysfunctions characterized by the presence of persistent deficits in social interaction, social communication, as well as restricted social interests and repetitive behaviors. Despite the increasing prevalence, no drug has been developed for the treatment of the core symptoms of ASD. Marijuana is regulated as a schedule 1 substance, with no acceptable therapeutic use, by the federal government. However, 29 states, the District of Columbia, Guam and Puerto Rico have comprehensive medical marijuana programs with an indication for a range of chronic illnesses. Among more than 100 cannabis compounds, cannabidiol (CBD) and ?? 9-tetrahydrocannabinol (THC) are the subjects of most studies. THC is the main psychoactive agent and demonstrates analgesic and anti-inflammatory properties. Cannabidiol can modulate the effects of THC and has neuroprotective, anticancer, anti-diabetic, antimicrobial and antipsychotic activities. The investigation was conducted to review the study and/or the potential use of marijuana or its components in the treatment of autism or autism-associated disorders.
